Tarceva - Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer
Key Data:
Drug (Brand/Generic)
Tarceva (erlotinib)
Company/Licensee
OSI Pharmaceuticals, Genetech, Roche
Therapy Class
Anti-neoplastic agent
Product Description
EGFR-tyrosine kinase inhibitor
Current Indication
NSCLC
Market Sector
Oncology
Development Status
Approved in US, Europe and Japan
